ClinicalTrials.gov
ClinicalTrials.gov Menu

Medications Development for the Treatment of Cannabis Related Disorders (MTC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01204723
Recruitment Status : Completed
First Posted : September 17, 2010
Last Update Posted : June 1, 2012
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
University of Virginia

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The primary objective of this application is to test the neurobehavioral mechanisms and effects of aprepitant as a new cessation agent for cannabis, tobacco or both.

Condition or disease Intervention/treatment Phase
Nicotine Withdrawal Marijuana Dependence Cannabis Dependence Nicotine Dependence Cannabis Abuse Drug: Placebo Aprepitant Drug: Active Aprepitant Phase 1

Detailed Description:
Stress (emotional, physical, social) facilitates drug seeking behavior through the activation of the HPA axis, autonomic nervous system, and brain DA systems. Furthermore, alterations within several neuropeptide systems (CRF, Substance P, and others) also contribute to the role of stress in addiction. Central to this project is that anxiety and stress responses are modulated by substance P and its preferred target, the NK1 receptor. Therefore the aim of this pilot clinical trial is to determine the safety and efficacy of aprepitant (a neurokinin 1 (NK1) receptor antagonist). We hypothesize that the NK1 receptor antagonist, aprepitant, will be safe, tolerable and efficacious at reducing the withdrawal symptoms, cue craving, and reinforcement value for both cannabis and tobacco resulting from the cessation of either or both drugs. We will assess this hypothesis in the context of a carefully controlled human laboratory study in which subjects (N=72) will be randomized in a 3 x 2 factorial design to one of 3 behavioral conditions; a) withdrawn from both substances, b) withdrawn from tobacco only, or c) withdrawn from cannabis only, and to receive one of 2 medication dose conditions: placebo or aprepitant (160 mg/day). Medication will be administered for 5 days, followed by a cue challenge, choice procedure, and then a consequence (i.e., oral cannabis or a cigarette or money) also on day 5.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 63 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Medications Development for the Treatment of Cannabis Related Disorders
Study Start Date : August 2009
Actual Primary Completion Date : January 2012
Actual Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Marijuana
Drug Information available for: Aprepitant

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Behavioral Condition 1
Nicotine patch (21 mg) plus placebo oral cannabis (0 mg; 3 times a day on days 2-4, given once on day 5)
 Drug: Placebo Aprepitant
Placebo Aprepitant 0 mg once daily for 5 days

Drug: Active Aprepitant
Active Aprepitant 160 mg once daily for 5 days
Experimental: Behavioral Condition 2
Placebo nicotine patch (0 mg) plus oral cannabis (10 mg, 3 times each day, days 2-4, day 5 given once)
 Drug: Placebo Aprepitant
Placebo Aprepitant 0 mg once daily for 5 days

Drug: Active Aprepitant
Active Aprepitant 160 mg once daily for 5 days
Experimental: Behavioral Condition 3
Placebo nicotine patch (0 mg) plus placebo oral cannabis (0 mg, 3 times each day days 2-4, day 5 given once)
 Drug: Placebo Aprepitant
Placebo Aprepitant 0 mg once daily for 5 days

Drug: Active Aprepitant
Active Aprepitant 160 mg once daily for 5 days


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. withdrawal symptom severity, measured on a 0 (not at all) to 3 (severe) scale [ Time Frame: collected on each study day ]
    Subjective experience of withdrawal symptoms for cannabis, tobacco, and both (eg: Irritability, Sleep difficulty, Chills, Nervousness)

  2. "craving" measured using the Marijuana craving questionaire and the tobacco craving questionaire [ Time Frame: collected on each study day ]
    Subjective measures of craving for cannabis, tobacco, and both Questionaires are anchored with strongly disagree to strongly agree (1-7)

  3. reinforcing effects, as measured using the Multiple Choice Questionaire [ Time Frame: collected each day of study ]
    Reinforcement value of cannabis and tobacco as measured by preference for money over the administration of either drug; questionaire has 70 questions and money value vs. drug ranges from 25 cents to 25 dollars 1-70.


Secondary Outcome Measures :
  1. sleep quality [ Time Frame: collected on each study day ]
    A VAS sleep questionnaire will be used each morning to assess daily sleep quality.

  2. Neurocognitive Function [ Time Frame: collected on days 1-4 of the study ]
    The purpose of examining the neurocognitive function of our participants on days 1-4 is to examine the safety of the co-administration of aprepitant at 160 mg/day with oral THC (dronabinol 10 mg) on brain function. Tasks used are the DSST - The Digit Symbol Substitution Test measures the learning of integrating visual and motor skills, and the SRTT- The Simple reaction Time Task is a well validated computerized test for assessing the effects of psychoactive drugs on performance.

  3. Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: each day of study ]
    Blood pressure, pulse, and a Systematic Assessment For Treatment Emergent Events (SAFTEE) are collected daily. Electrocardiograms (EKGs) are collected at baseline and discharge.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Must meet DSM-IV/ICD-10 criteria for cannabis abuse or dependence
  • Must be non-treatment seeking individuals
  • Participant does not meet DSM-IV criteria for any current (i.e., criteria met at any point in the past 30 days) dependence on a substance other than alcohol, nicotine, caffeine, or marijuana or physiological dependence on alcohol requiring medical detoxification.
  • No subjects who have trouble reading the English language or visual or hearing problems that may interfere with the collection of data
  • Not currently taking other medications (with the exception of oral contraceptives) that would preclude safe participation in this study
  • Must test negative for pregnancy prior to inclusion
  • females using birth control pills must agree to use a condom during intercourse for 1 month after participation in study because the study medication will decrease the effectiveness of the birth control pill rendering it ineffective
  • Should be in general good health
  • No evidence of recent use of other illicit drugs on a urine toxicity screen prior to admission

Exclusion Criteria:

  • Major current (within last 90 days) Axis I psychopathology (e.g., major depressive disorder, bipolar disorder, schizophrenia)
  • Presence of significant medical illness (e.g., diabetes, cardiovascular disease, hypertension, cancer, epilepsy, kidney disease)
  • Current, repeated illicit drug use (other than marijuana)
  • Subject is breastfeeding or pregnant
  • Concurrent therapy with drugs known to inhibit CYP3A4 activity
  • Request for drug treatment
  • Current parole or probation
  • Recent history of significant violent or suicide behavior
  • Allergic to sesame oil
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01204723


Locations
United States, Virginia
Clinical Pharmacological Research Unit (CPRU), University of Virginia School of Medicine
Charlottesville, Virginia, United States, 22903
University of Virginia Center for Addiction Education and Treatment (UVA CARE)
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
University of Virginia
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Heather M Haughey, Ph.D. University of Virginia School of Medicine, Dept. Psychiatry and Neurobehavioral Sciences
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: University of Virginia
ClinicalTrials.gov Identifier: NCT01204723     History of Changes
Other Study ID Numbers: 14392
R01DA027131 ( U.S. NIH Grant/Contract )
First Posted: September 17, 2010    Key Record Dates
Last Update Posted: June 1, 2012
Last Verified: May 2012

Keywords provided by University of Virginia:
Marijuana Abuse
cannabis
Nicotine Dependence
Nicotine Withdrawal
neurokinin Receptor
NK1 Receptor antagonist
Substance P
Recurrence
Substance Withdrawal Syndrome
Substance-Related Disorders
Disorders of Environmental Origin
Mental Disorders
 Disease Attributes
Pathologic Processes
Tetrahydrocannabinol
Therapeutic Uses
Psychotropic Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Narcotic Antagonists

Additional relevant MeSH terms:
Marijuana Abuse
Tobacco Use Disorder
Substance Withdrawal Syndrome
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Nicotine
Aprepitant
Fosaprepitant
Peripheral Nervous System Agents
Analgesics
Molecular Mechanisms of Pharmacological Action
 Ganglionic Stimulants
Autonomic Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Sensory System Agents
Antiemetics
Gastrointestinal Agents
Neurokinin-1 Receptor Antagonists